No Detail Found!

Evaluation of the Effect of Favipiravir on QT Intervals in COVID-19 Patients with and without Diabetes Mellitus

Author(s)
Mustafa Dogan Department of Infectious Diseases, Namik Kemal University School of Medicine,Tekirdag,Turkiye
Derya Baykiz Department of Cardiology, Istanbul University School of Medicine,Istanbul,Turkiye
Ibrahim Yilmaz Department of Pharmacovigilance, Republic of Turkey, Ministry of Health, Doctor Ismail Fehmi Cumalioglu City Hospital, Tekirdag, Turkiye; Department of Medical Services and Techniques, Istanbul Rumeli University, Vocational School of Health Services, Istanbul, Turkey
Fatma Bahar Hacioglu Kasim Clinics of Radiology, Republic of Turkey, Ministry of Health, Doctor Ismail Fehmi Cumalioglu City Hospital,Tekirdag,Turkiye
Betul Ekiz Bilir Clinics of Endocrinology and Metabolic Diseases, Republic of Turkey, Ministry of Health, Doctor Ismail Fehmi Cumalioglu City Hospital,Tekirdag,Turkiye
Bulent Bilir Department of Internal Medicine, Namik Kemal University School of Medicine,Tekirdag,Turkiye
Abstract
Objective: To evaluate the e ect of favipiravir administered to diabetic and non-diabetic COVID-19 patients on the QT/QTc interval. Study Design: Analytical study. Place and Duration of the Study: Republic of Turkey, Ministry of Health,State Hospital, Corlu, Tekirdag, Turkiye, from March to September 2021. Methodology: Electrocardiogram (ECG) analysis was performed on all participants (n=180) divided into four groups.Group 1 included only healthy volunteers. Group 2 included only cases diagnosed with T2DM. Group 3 included only severe acute respiratory syndrome coronavirus-2 (SARS-Cov-2) cases. Group 4 included cases diagnosed with both SARS and T2DM. Favipiravir was administered only to the cases in Group 3 and Group 4. In the cases that were administered favipiravir, the QT/QTc interval was calculated and recorded at di erent time intervals on the rst and fth days of the therapy. The di erence between groups was determined by Tukeye s test after ANOVA. Pearson s correlation test was usedto determine whether there was a linear relationship between two numericals.The alpha signi cance value was determined to be <0.05 in all statistical analyses. Results: When all groups were compared, it was seen that both QT and QTc values increased in Groups 3 and 4, which were administered favipiravir (p <0.05). Favipiravir may cause an increased risk of ventricular and atrial arrhythmias. Conclusion: Favipiravir may cause QT interval prolongation, particularly in SARS-Cov-2 patients diagnosed with T2DM.
Publication Details
Page(s) 659-666
Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 34, Issue: 6, Year: 2024

Request the full text from PASTIC

Keywords
type 2 diabetes mellitus, COVID-19, COVID-19, Favipiravir, Drug-induced long QT syndrome, Intra-infarct haemorrhage
0

Citations

0

Downloads

105

Views